<i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i> genes mutations in tumor cells of various localizations and their impact on the treatment outcomes of patients with multiple myeloma
Maya Soloveva(Ministry of Health of the Russian Federation), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), M. V. Solovev(Ministry of Health of the Russian Federation), Anastasia V. Popova(Ministry of Health of the Russian Federation), N. V. Risinskaya(Ministry of Health of the Russian Federation), I. A. Yakutik(Ministry of Health of the Russian Federation), A. B. Sudarikov(Ministry of Health of the Russian Federation), T. N. Obukhova(Ministry of Health of the Russian Federation), E. E. Nikulina(Ministry of Health of the Russian Federation), B. V. Biderman(Ministry of Health of the Russian Federation)
Cited by 0
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59